Coronary Artery Disease

Cardiovascular·MeSH: Coronary Artery Disease

Prevalence

3103.7 / 100K

Incidence

164.9 / 100K/yr

16 drugs in development·15 companies·45 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
amlodipine	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
ammonia n 13	BRIGHT MINDS BIOSCIENCES INC. (DRUG)
fludeoxyglucose f18	BRIGHT MINDS BIOSCIENCES INC. (DRUG)
isosorbide mono	EXELIXIS, INC. (EXEL)
nitroglycerin	DR REDDYS LABORATORIES LTD (RDY)
technetium tc 99m sestamibi	Cardinal Health Inc. (CAH)

Phase 3(2)

Drug	Company
generx	Gene Biotherapeutics, Inc. (CRXM)
xtr004	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)

Phase 2(3)

Drug	Company
aroxxen	PRF Technologies Ltd. (PRFX)
Aroxxen	Crinetics Pharmaceuticals, Inc. (CRNX)
selatogrel	Innovation Pharmaceuticals Inc. (IPIX)

Phase 1(2)

Drug	Company
selatogrel	Viatris Inc (VTRS)
VERVE-102	Travere Therapeutics, Inc. (TVTX)

Phase 4(3)

Drug	Company
High dose potent statin	CYTOKINETICS INC (CYTK)
High dose potent statin	UNITED THERAPEUTICS Corp (UTHR)
prasugrel or ticagrelor	Cidara Therapeutics, Inc. (CDTX)

BioSniper tracks 16 drugs in development for Coronary Artery Disease across 15 companies.

There are 45 clinical trials targeting Coronary Artery Disease tracked by BioSniper.

The estimated prevalence of Coronary Artery Disease is approximately 3103.7 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.